<unk>  or JTT-705 is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012.  The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C).  Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health.
Dalcetrapib
Brigatinib
Evacetrapib
Enasidenib
Ivosidenib
Fostamatinib
Vismodegib
Baricitinib